PRCT 2-WEEK DEADLINE ALERT: PROCEPT BioRobotics Corporation Investors Alerted to September 22, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) investors are alerted to a September 22, 2026 lead plaintiff deadline in a class action lawsuit concerning repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels driven by repeated, late-quarter, bulk discounts. The lawsuit seeks to represent investors who purchased or otherwise acquired PROCEPT common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that during the Class Period, the defendants withheld crucial information from investors about PROCEPT's business, operations, and financial condition. Its focus is on the propriety of the company's statements and omissions related to handpiece sales practices in the U.S., including repeated touting of growth in those sales. More specifically, the complaint alleges that the company's utilization of an extensive discount program to incentivize its customers to place bulk orders exceeding customers' procedures demands, pulling forward sales at the expense of future periods and, thereby, artificially inflating reported unit sales and revenues. Investors began to learn the truth through a series of partial disclosures, each of which drove the price of PROCEPT shares sharply lower. On August 6, 2025, PROCEPT announced its Q2 2025 financial results, revealing that the company's handpiece sales unexpectedly deteriorated, missing consensus estimates by a wide margin. Then, on November 4, 2025 PROCEPT reported its Q3 2025 results, again missing expected handpiece unit sales. During the corresponding earnings call, management slashed annual handpiece unit sales guidance to allow for the "optimization of field inventory[,]". Finally, on February 25, 2026 PROCEPT announced Q4 2025 results. For the first time, the company disclosed the actual number of procedures in the field and revealed that U.S. handpiece sales materially exceeded procedures in each quarter since Q1 2023. Cumulative excess customer inventory of handpieces were over 10,000 units and U.S. handpiece sales sequentially cratered by 30%. Management then said that the company was eliminating its bulk order discount program which was designed to incentivize customers to make large purchases during "the final weeks" of every quarter. As a result of these events, by February 25, the price of PROCEPT shares had steadily declined by $22.06, or over 48% from the close on August 6, 2025. "We're focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications," said Reed Kathrein.